198 related articles for article (PubMed ID: 20458652)
1. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Taverna C; Bargetzi M; Betticher D; Gmür J; Gregor M; Heim D; Hess U; Ketterer N; Lerch E; Matthes T; Mey U; Pabst T; Renner C
Swiss Med Wkly; 2010; 140():w13054. PubMed ID: 20458652
[TBL] [Abstract][Full Text] [Related]
2. [Current treatment strategies for multiple myeloma].
Mey UJ
Ther Umsch; 2010 Oct; 67(10):527-35. PubMed ID: 20886459
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma: novel approaches for relapsed disease.
Lonial S
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S18-23. PubMed ID: 18282362
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide efficacy in bortezomib-resistant myeloma.
Gozzetti A; Crupi R; Defina M; Bocchia M
Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
[No Abstract] [Full Text] [Related]
5. Lenalidomide for bortezomib-resistant multiple myeloma.
Briani C; Berno T; Campagnolo M; Zambello R
Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
[No Abstract] [Full Text] [Related]
6. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
7. [It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Takamatsu Y
Rinsho Ketsueki; 2012 Jun; 53(6):587-93. PubMed ID: 22790633
[No Abstract] [Full Text] [Related]
8. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma.
Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
[TBL] [Abstract][Full Text] [Related]
15. Advances in treatment for relapses and refractory multiple myeloma.
Richards T; Weber D
Med Oncol; 2010 Jun; 27 Suppl 1():S25-42. PubMed ID: 20213220
[TBL] [Abstract][Full Text] [Related]
16. Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland.
Taverna C; Voegeli J; Trojan A; Olie RA; von Rohr A
Swiss Med Wkly; 2012; 142():w13562. PubMed ID: 22544478
[TBL] [Abstract][Full Text] [Related]
17. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
18. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
Mellstedt H; Gimsing P; Waage A
Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535
[No Abstract] [Full Text] [Related]
20. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
